RxDoctor Payments Data

Evelyn Li, MD

Cardiology · Hayward, CANPI 1235142761

Payments from drug & device makers

What this record shows

This record is dominated by other: $5,077 of the $6,202 with a category attached, or 81.9%. Medtronic accounts for 90.1% of it on its own, with 12 other manufacturers making up the rest. 2024 is the largest year on record at $5,152, more than ten times the $210 reported in 2019.

$6,202in general payments, 2019–2025

Across 39 payments — averaging $159.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$6K
  • Boehringer Ingelheim$186
  • Electromed, Inc.$89
  • Johnson & Johnson$66
  • Pfizer$50
  • Amgen$48
  • plus $173 from 7 others

What the payments were for

  • Food & beverage$1,12518%
  • Other$5,07782%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,202 in reported general payments places this provider in the 85th percentile of 156 cardiology providers in California.

See all cardiology providers in California

Medicare billing

Part B allowed, 2024
$2,954,136
Medicare patients
128
Services billed
42,386

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin150$93,877
XareltoRivaroxaban94$57,817
MultaqDronedarone Hcl43$38,846
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr47$19,807
KerendiaFinerenone31$18,910
FarxigaDapagliflozin Propanediol32$18,755
EliquisApixaban19$11,926
Rasagiline Mesylate50$11,400
RestasisCyclosporine17$10,971
LinzessLinaclotide18$8,704
BelsomraSuvorexant21$8,542
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog24$6,844
JanuviaSitagliptin Phosphate14$6,779
Praluent PenAlirocumab13$6,429
Spiriva HandihalerTiotropium Bromide12$5,954

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$186$93,877150 claims
Johnson & JohnsonXarelto$66$57,81794 claims
PfizerEliquis$50$11,92619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 156 cardiology providers in California.

Other cardiology in Hayward

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →